Artikel ; Online: Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.
Multiple sclerosis and related disorders
2020 Band 44, Seite(n) 102341
Abstract: Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.: Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on ... ...
| Abstract | Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2. Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology. Results: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection. Conclusions: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production. |
|---|---|
| Mesh-Begriff(e) | Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19 Serological Testing ; Female ; Humans ; Immunologic Factors/therapeutic use ; Male ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy |
| Chemische Substanzen | Antibodies, Monoclonal, Humanized ; Immunologic Factors ; ocrelizumab (A10SJL62JY) |
| Schlagwörter | covid19 |
| Sprache | Englisch |
| Erscheinungsdatum | 2020-06-26 |
| Erscheinungsland | Netherlands |
| Dokumenttyp | Case Reports ; Letter ; Review |
| ZDB-ID | 2645330-7 |
| ISSN | 2211-0356 ; 2211-0348 |
| ISSN (online) | 2211-0356 |
| ISSN | 2211-0348 |
| DOI | 10.1016/j.msard.2020.102341 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.